viewLeanLife Health

LeanLife signs letter of intent with Ecovatec for testing and production

The deal will allow LeanLife to move to long-term production of its Omega-3 plant-based products

flax seeds
Using the Ecovatec facility paves the way for the immediate commercialization of LeanLife's plant-based food products

LeanLife Health Inc (CSE:LLP) announced Monday that it has signed a letter of intent with the nutraceutical manufacturing company Ecovatec Solutions Inc to access its facilities for testing and production.

The deal will allow LeanLife to move from testing and the creation of samples to long-term production of its Omega-3 plant-based products.

"Completion of this Letter of Intent marks a significant milestone for LeanLife Health as it allows the Company to move towards immediate commercialization without bearing any substantial overhead,” said Stan Lis, CEO of LeanLife. “Leanlife intends to start sending samples of its plant-based Food products to prospective customers as well as fill existing product orders on hand. Accordingly, and following a definitive agreement, Leanlife will be able to generate revenues this year while protecting our proprietary process.”

READ: LeanLife hires food safety consultants to help ensure omega-3 products meet food safety requirements

Under the terms of the agreement, LeanLife will be able to conduct its work at Ecovatec’s manufacturing facility in Abbotsford, British Columbia.

Upon the signing of a Phase 1 testing agreement, LeanLife hopes to introduce a more efficient sanitary manufacturing process. This testing is set to improve the production process and generate additional intellectual property for LeanLife.

“Following a successful trial run of the new process, samples will be tested to ensure product quality, after which further samples will be created to send to customers for their own qualification,” LeanLife said in its release.

READ: LeanLife Health production equipment due soon as it sets up first facility in North America

As part of the deal, LeanLife also intends to enter into a Phase2 interim production agreement which will immediately allow it to begin meeting demand from customers for its products. A Phase 3 long-term production arrangement is another option available to LeanLife under the letter of intent if customer demand accelerates.

Using the Ecovatec facility with its own equipment allows LeanLife to avoid the overhead costs and capital required to acquire its own production facility while allowing for the immediate commercialization of its plant-based food products.

LeanLife Health’s products are extractions from flax seed, a plant-based source of Omega 3. The products can be used as food additives or as nutraceuticals and have been used to make bread, noodles, cheese, yogurt, juice and milk products for the European market.

LeanLife shares finished up 5.88% to hit C$0.09 on Friday.

Contact Ellen Kelleher at [email protected]

Quick facts: LeanLife Health

Price: 0.045 CAD

Market: CSE
Market Cap: $4.35 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of LeanLife Health named herein, including the promotion by the Company of LeanLife Health in any Content on the Site, the Company receives from...


3 min read